Patent EP0417709A2 successfully refreshed from Google Patents.
Patent US4670461A successfully refreshed from Google Patents.
US4670461A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Formaldehyde derivatives of mitindomide
Assignee: United States Department of Health and Human Services
•
Filing: 1984-04-26
•
Granted: 1987-06-02
•
Expires: 2004-04-26
Abstract
Abstract New substituted, formaldehyde derived mitindomide and methods of preparing the same are disclosed. The novel compounds are water soluble and have anti-neoplastic activity. The formaldehyde derived mitindomide is prepared by reacting mitindomide with formaldehyde and further acetylating the derived hydroxymethyl compound. The amido compounds can be derived by reacting mitindomide in mannich fashion, i.e-formaldehyde and secondary amines.
Inventors
- 👤 Rudiger D. Haugwitz
- 👤 Venkatachala L. Narayanan
- 👤 Leon H. Zalkow
- 👤 Howard M. Deutsch
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:37
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/08
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
54 words
A compound of the formula: ##STR9## wherein R is hydrogen, lower alkyl, phenyl, benzyl or --COOH and wherein R 1 is hydrogen, or --COR 6 and wherein R 6 is alkyl, monoaminoalkyl, monodialkylaminoalkyl, monocarboxamidoalkyl, monodialkylcarboxamidoalkyl, monohydroxyalkyl, --CH(NH 2 )CH 2 C 6 H 5 , monocarboxyalkyl, or the physiologically acceptable acid addition salts thereof.
Claim 2
Dependent Claim
54 words
A compound of the formula: ##STR9## wherein R is hydrogen, lower alkyl, phenyl, benzyl or --COOH and wherein R 1 is hydrogen, or --COR 6 and wherein R 6 is alkyl, monoaminoalkyl, monodialkylaminoalkyl, monocarboxamidoalkyl, monodialkylcarboxamidoalkyl, monohydroxyalkyl, --CH(NH 2 )CH 2 C 6 H 5 , monocarboxyalkyl, or the physiologically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
50 words
A compound of the formula: ##STR10## wherein R is hydrogen, lower alkyl, phenyl, benzyl or --COOH and wherein R 3 and R 4 are alkyl, monohydroxy-substituted alkyl, monohalosubstituted alkyl, or R 3 and R 4 together with the nitrogen atom are ##STR11## or the physiologically acceptable acid addition salts thereof.
Claim 4
Dependent Claim
50 words
A compound of the formula: ##STR10## wherein R is hydrogen, lower alkyl, phenyl, benzyl or --COOH and wherein R 3 and R 4 are alkyl, monohydroxy-substituted alkyl, monohalosubstituted alkyl, or R 3 and R 4 together with the nitrogen atom are ##STR11## or the physiologically acceptable acid addition salts thereof.
Claim 5
Dependent Claim
10 words
The compound of claim 1 wherein R 1 is Hydrogen.
Claim 6
Dependent Claim
7 words
The compound of claim 1 being 4,8-Ethenopyrrolo[3',4':3,4]cyclobut[1,2-f]isoindole-1,3,5,7(2H,6H)-tetrone,3a,3b,4,4a,7a,8,8a,8b-octahydro-2-,6-bis(hydroxymethyl).
Claim 7
Dependent Claim
16 words
The compound of claim 1 wherein said compound is in the form of an acid-addition salt.
Claim 8
Dependent Claim
31 words
The compound of claim 5 wherein said acid-addition salt is selected from the group consisting of hydrohalide, sulfate, nitrate, phosphate, oxalate, tartrate, acetate, maleate, fumarate, citrate, succinate, methanesulfonate, benzenesulfonate and toluenesulfonate.
Claim 9
Dependent Claim
29 words
An antineoplastic composition for treating murine tumors comprising an antineoplastically effective amount of the compound of claim 1 as an active ingredient and a pharmaceutically acceptable additive or carrier.
Claim 10
Dependent Claim
29 words
An antineoplastic composition for treating murine tumors comprising an antineoplastically effective amount of the compound of claim 2 as an active ingredient and a pharmaceutically acceptable additive or carrier.
Claim 11
Dependent Claim
24 words
A method of treating mammals afflicted with murine tumors comprising administering to said mammals an antineoplastically effective amount of the compound of claim 1.
Claim 12
Dependent Claim
24 words
A method of treating mammals afflicted with murine tumors comprising administering to said mammals an antineoplastically effective amount of the compound of claim 2.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-01 | 1990-12-01 | 1991-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-01 | 1994-12-01 | 1995-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-01 | 1998-12-01 | 1999-06-02 | $7700.00 | Window Closed / Lapsed |